New ISPOR Article Compares Net Drug Prices and ICER’s Value-Based Prices
A new article, published in ISPOR’s Value in Health journal, assesses drug prices by comparing net prices to the Institute [...]
CEVR Researchers Publish Article on Strengths of Value-Based Healthcare and HTAs
Leading researchers at Tufts University School of Medicine’s Center for the Evaluation of Value and Risk in Health (CEVR) have [...]
ICER Publishes Fairness Assessment Protocol in New Healthcare Equity Initiative
The Institute for Clinical and Economic Review (ICER) will begin considering barriers to drug access in an effort to promote [...]
ICER Considers Payers’ Drug Coverage in Fairness Assessment
The Institute for Clinical and Economic Review (ICER) has decided to expand its role to consider whether a health insurance [...]
Lupus Foundation Provides Patient Perspective in ICER Drug Assessment
The Institute for Clinical and Economic Review (ICER) reviewed two drugs (voclosporin and belimumab) for use in cases of lupus [...]
Bernstein Analysts Say Value-Based Pricing System Feasible; ICER Assessments Could Lower Pharma Revenue by 15%
One proposed method that could reduce drug prices is the use of a value-based system. A recent report by Bernstein [...]
ICER President Discusses Market Outlook Post-Pandemic Amid Drug Pricing Debates
In a recent interview, President of the Institute for Clinical and Economic Reform (ICER) Dr. Steve Pearson spoke about how [...]
ESG Measures Could Incorporate Drug Pricing Data
Environment, social, and governance (ESG) measures indicate how pharmaceutical companies consider the global impact of their policies. Now, some analysts [...]
Bernstein Analyst Considers Impact of ICER Analytics in Lowering Prescription Drug Prices
Analyst Ronny Gal of Bernstein put forth an investor note where he discussed methods that could bring down high prescription [...]
ISPOR Panelists Discuss Incorporating the Patient Voice in Prescription Drug Value Assessments
In a recent virtual ISPOR meeting, panelists discussed how to adjust methods such that patient experiences can be better incorporated [...]
Report Suggests Corporate Environmental and Social Goals Should Include ICER Pricing Assessments
Bernstein analysts suggest that companies implementing environment, social, and governance (ESG) actions should consider drug pricing. They might consider incorporating [...]
ICER Announces Cloud-Based ICER Analytics Platform
The Institute for Clinical and Economic Review (ICER) has announced the launch of ICER Analytics. The new cloud-based tool is [...]
Fate of Biogen’s Alzheimer’s Disease Drug Remains Uncertain
Biogen is awaiting the Food and Drug Administration’s decision regarding its Alzheimer’s disease drug, aducanumab. However, mixed data regarding the [...]
ICER Will Consider AstraZeneca Asthma Treatment
The Institute for Clinical and Economic Review (ICER) is set to evaluate AstraZeneca’s tezepelumab. ICER will consider the efficacy and [...]
ICER Reveals Final Evidence Report on Three Multiple Myeloma Therapies
The Institute for Clinical and Economic Review (ICER) has announced a Final Evidence Report evaluating three therapies for use in [...]
ICER Publishes Draft Evidence Report on Alzheimer’s Disease Drug
The Institute for Clinical and Economic Review (ICER) published a Draft Evidence Report regarding Biogen’s aducanumab. The drug is designed to treat [...]
ICER’s Protocol on Unsupported Price Increases Discusses 250 Drugs
The Institute for Clinical and Economic Review (ICER) recently published a protocol detailing how it determines unjustified price increases. The [...]
ICER’s New Whitepaper Features Insight on FDA’s Accelerated Approval Pathway and Proposes Drug Pricing Reform
The Institute for Clinical and Economic Review (ICER) published a whitepaper discussing the Food and Drug Administration’s Accelerated Approval Pathway (AAP). The [...]
New Study Examines Cost-Effectiveness, Equity, Caregiver Burden, and Other Value Elements in 20 ICER Reports
A new article, published in the Journal of Managed Care and Specialty Pharmacy, examines 32 value elements, including health equity [...]
New Podcast Featuring ICER President on Consequences of High Drug Prices and Thoughts on New Cholesterol-Reducing Drugs
A recent Managed Healthcare Executive podcast featured ICER President and Founder Dr. Steven Pearson. ICER recently published a report on [...]
ICER Whitepaper on Successfully Navigating the FDA’s Accelerated Approval Pathway
Today, ICER (the Institute for Clinical and Economic Review) announced a new whitepaper on understanding and navigating the FDA’s accelerated [...]
ICER and Aetion Collaborate to Use RWE in Hereditary Angioedema Pilot Study
ICER recently announced a partnership with Aetion. ICER will use Aetion’s RWE (real world evidence) in revising its assessment on [...]
HTA Whitepaper Discusses Resulting Value and Economic Benefits
In a whitepaper by researchers at the USC Schaeffer Center and Aspen Institute Advisory Panel, the authors discuss how an [...]
ICER Publishes Methodology on Evaluating Unsupported Drug Price Increases
ICER has released a protocol detailing how it analyses UPIs (Unsupported Price Increases) for prescription drugs in the United States. [...]
ICER to Consider Aetion RWE in Revision of Hereditary Angioedema Therapy Report
ICER (the Institute for Clinical and Economic Review) has announced its decision to utilize RWE (real world evidence) data in [...]